| Does Enanta Pharmaceuticals (ENTA) Have the Potential to Rally 189.58% as Wall Street Analysts Expect? |
The consensus price target hints at an 189.6% upside potential for Enanta Pharmaceuticals (ENTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-05-15 15:00:38 |
Czytaj oryginał (ang.) |
| Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates |
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to loss of $1.47 per share a year ago. |
zacks.com |
2025-05-12 22:10:44 |
Czytaj oryginał (ang.) |
| Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025 |
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025. |
businesswire.com |
2025-04-08 11:00:00 |
Czytaj oryginał (ang.) |
| Enanta Pharmaceuticals (ENTA) Moves to Buy: Rationale Behind the Upgrade |
Enanta Pharmaceuticals (ENTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2025-02-14 15:06:12 |
Czytaj oryginał (ang.) |
| Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates |
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.05 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.58 per share a year ago. |
zacks.com |
2025-02-10 20:11:07 |
Czytaj oryginał (ang.) |
| Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024 |
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal first quarter ended December 31, 2024. “2025 is primed to be a pivotal year for Enanta as we execute on multiple catalysts across our pipeline, including progression of our RSV compounds and expansion of our immunology portfolio. Recruitment for RSV. |
businesswire.com |
2025-02-10 18:01:00 |
Czytaj oryginał (ang.) |
| Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit |
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the United States District Court of Massachusetts (“the Court”) has issued a ruling on a summary judgment motion filed by Pfizer, Inc. in connection with Enanta's patent infringement lawsuit seeking damages for infringement of U.S. Patent No. 11,358,953 (“the '953 Patent”) i. |
businesswire.com |
2024-12-24 09:00:00 |
Czytaj oryginał (ang.) |
| Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last? |
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term. |
zacks.com |
2024-12-23 12:46:20 |
Czytaj oryginał (ang.) |
| Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) |
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced positive topline results from the first-in-pediatrics Phase 2 study evaluating zelicapavir in hospitalized and non-hospitalized children aged 28 days to 36 months with respiratory syncytial virus (RSV). An antiviral effect was observed for the primary and secondary virology endpoi. |
businesswire.com |
2024-12-09 08:30:00 |
Czytaj oryginał (ang.) |
| Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV) |
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the company will hold a conference call and webcast on Monday, December 9 at 8:30 a.m. ET to share topline results from RSVPEDs, a first-in-pediatrics Phase 2 study evaluating zelicapavir in hospitalized and non-hospitalized children aged 28 days to 36 months with respiratory sync. |
businesswire.com |
2024-12-06 19:00:00 |
Czytaj oryginał (ang.) |
| Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates |
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.36 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.33 per share a year ago. |
zacks.com |
2024-11-25 20:11:16 |
Czytaj oryginał (ang.) |
| Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024 |
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal fourth quarter and year-ended September 30, 2024. “Our fiscal fourth quarter was an exciting time for Enanta as we announced positive data from a Phase 2a human challenge study of EDP-323, our RSV L-inhibitor. We believe these results are among the. |
businesswire.com |
2024-11-25 18:01:00 |
Czytaj oryginał (ang.) |
| Enanta Pharmaceuticals (ENTA) Surges 5.6%: Is This an Indication of Further Gains? |
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term. |
zacks.com |
2024-10-02 12:56:09 |
Czytaj oryginał (ang.) |
| Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV) |
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With RSV. |
businesswire.com |
2024-09-26 10:00:00 |
Czytaj oryginał (ang.) |
| Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates |
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.07 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to loss of $1.86 per share a year ago. |
zacks.com |
2024-08-05 22:10:18 |
Czytaj oryginał (ang.) |
| Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter |
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter. |
businesswire.com |
2024-08-05 20:01:00 |
Czytaj oryginał (ang.) |
| Enanta Pharmaceuticals (ENTA) Soars 6.7%: Is Further Upside Left in the Stock? |
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2024-07-15 15:11:06 |
Czytaj oryginał (ang.) |
| Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference |
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024 at 7:30 a.m. ET in New York, NY. A live webcast of the even. |
businesswire.com |
2024-05-29 11:00:00 |
Czytaj oryginał (ang.) |
| Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference |
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the JMP Securities Life Sciences Conference on May 14, 2024 at 10:00 a.m. ET in New York, NY. A live webcast of the ev. |
businesswire.com |
2024-05-07 11:00:00 |
Czytaj oryginał (ang.) |
| Enanta Pharmaceuticals, Inc. (ENTA) Q2 2024 Earnings Call Transcript |
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA ) Q2 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Jennifer Viera - Investor Relations Jay Luly - President and Chief Executive Officer Paul Mellett - Chief Financial Officer Scott Rottinghaus - Chief Medical Officer Tara Kieffer - Chief Product Strategy Officer Conference Call Participants Eric Joseph - JPMorgan Roy Buchanan - Citizens JMP Nik Gasic - Leerink Partners Jay Olson - Oppenheimer Operator Good afternoon and welcome to Enanta Pharmaceuticals' Fiscal Second Quarter Financial Results Conference Call. At this time, all participants are on a listen-only mode. |
seekingalpha.com |
2024-05-07 00:34:10 |
Czytaj oryginał (ang.) |
| Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue Estimates |
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.47 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to loss of $1.79 per share a year ago. |
zacks.com |
2024-05-06 22:11:08 |
Czytaj oryginał (ang.) |
| Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET |
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal second quarter ended March 31, 2024. “At Enanta, we are committed to advancing the first antiviral treatment for RSV, and more broadly developing important medicines in virology and immunology. Our commitment is highlighted by our goal to deliver mu. |
businesswire.com |
2024-05-06 20:01:00 |
Czytaj oryginał (ang.) |
| Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that effective April 29, 2024, the Compensation Committee of Enanta Pharmaceuticals' Board of Directors granted employment inducement awards to Matthew P. Kowalsky, Enanta's new Chief Legal Officer, consisting of a non-qualified stock option to purchase 150,000 shares of its commo. |
businesswire.com |
2024-04-30 11:10:00 |
Czytaj oryginał (ang.) |
| Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer |
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the appointment of Matthew P. Kowalsky, J.D., as Chief Legal Officer. In this role, he will lead all legal and compliance activities for Enanta, as well as provide strategic guidance and corporate governance oversight. “I'm pleased to welcome Matt to Enanta. The breadth of his leg. |
businesswire.com |
2024-04-30 11:00:00 |
Czytaj oryginał (ang.) |
| Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024 |
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2024, after the U.S. market closes on May 6, 2024. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta's business, includ. |
businesswire.com |
2024-04-29 11:00:00 |
Czytaj oryginał (ang.) |
| Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024 |
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for indications in virology and immunology, today announced that data from the company's SPRINT (SARS-Cov-2 PRotease INhibitor Treatment) study of EDP-235 has been accepted for a poster presentation at ESCMID Global 2024 (formerly ECCMID) being held April 27–30 in Barcelona, Spain. The poster presentation includes primary and post-hoc a. |
businesswire.com |
2024-04-17 11:00:00 |
Czytaj oryginał (ang.) |